Results of the Rapidec® CARBA NP test in El Salvador

Authors

  • José Eduardo Oliva Marín National Institute of Health of El Salvador https://orcid.org/0000-0002-6005-0558
  • María José Luna Boza National Public Health Laboratory of El Salvador
  • Miguel Oscar Grande Figueroa National Public Health Laboratory of El Salvador
  • Reina Esmeralda Villatoro Ventura Executive Secretariat of the Council of Ministers of Health of Central America (SE-COMISCA) https://orcid.org/0000-0002-2412-2083
  • René Guillermo Santos Herrera ECHO proyect and Executive Secretariat of the Council of Ministers of Health of Central America (SE-COMISCA)
  • Ana Patricia Orellana de Figueroa Coordination of the National Network of Clinical Laboratories, Ministry of Health of El Salvador (MINSAL)
  • Milagro Arenys Vélasquez Escobar San Miguel National Hospital, San Miguel, El Salvador
  • Zonia Elizabeth Cruz National Women's Hospital, San Salvador, El Salvador
  • Ana Alejandra Rivera Laínez Santa Ana National Hospital, Santa Ana, El Salvador
  • Patricia Evelyn Henríquez Benjamin Bloom National Children's Hospital, San Salvador, El Salvador
  • Patricia Danne Orellana Morales Rosales National Hospital, San Salvador, El Salvador
  • Naomi Iihoshi Executive Secretariat of the Council of Ministers of Health of Central America (SE-COMISCA)
  • David Saúl Rodriguez Araujo Executive Secretariat of the Council of Ministers of Health of Central America (SE-COMISCA)
  • Rhina Domínguez National Institute of Health of El Salvador https://orcid.org/0000-0001-7860-0602

DOI:

https://doi.org/10.5377/alerta.v6i1.15451

Abstract

Dear editor:

Nowadays, there are commercially available rapid carbapenemase tests that can generate results in less than two hours. One of these tests is Rapidec® CARBA NP, based on the direct detection of carbapenemase hydrolysis by carbapenemase-producing bacteria. The agility in detecting these enzymes is relevant in our country, as described in the article by Villatoro et al. in Alerta in 2018. They reported that carbapenemase-producing bacteria were isolated in 26 of 31 hospitals in El Salvador from 2014 to 20161.

This test analyzed the presence of carbapenemases in 122 isolated samples belonging to the Enterobacteriaceae family, as well as in non-fermenting bacilli, with decreased susceptibility or resistance profiles to any of the following carbapenemics: ertapenem, imipenem or meropenem. These were analyzed from five hospitals in the public health network of El Salvador between March 2020 and August 2021.

 

Downloads

Download data is not yet available.
Abstract
285
PDF (Español (España)) 249
PDF ENG 86
Vol. 6, 2023

Downloads

Published

2023-01-30

How to Cite

Oliva Marín, J. E., Luna Boza, M. J., Grande Figueroa, M. O., Villatoro Ventura, R. E., Santos Herrera, R. G., Orellana de Figueroa, A. P., Vélasquez Escobar, M. A., Cruz, Z. E., Rivera Laínez, A. A., Henríquez, P. E., Orellana Morales, P. D., Iihoshi, N., Rodriguez Araujo, D. S., & Domínguez, R. (2023). Results of the Rapidec® CARBA NP test in El Salvador. Alerta, Revista científica Del Instituto Nacional De Salud, 6(1), 88–90. https://doi.org/10.5377/alerta.v6i1.15451

Issue

Vol. 6 No. 1 (2023)

Section

Letter to the editor

License

Copyright (c) 2023 José Eduardo Oliva Marín

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Privacy statement:

Alerta articles are published under license Creative Commons 4.0 CC BY: https://creativecommons.org/licenses/by/4.0/

Authorship rights

Revista Alerta gives the authors exclusive control of their work and the right to be acknowledged and cited.

Most read articles by the same author(s)